Search Results for “Novo Nordisk ” – Page 9 – media

Let’s look at the suspense of the King of Medicine

On October 31, Merck was the first to release its third-quarter financial report. In the first three quarters, K drug performed as well as ever, with sales of US$21.646 billion, a year-on-year increase of 18%, and annual sales are expected to exceed US$29 billion. According to this trend, K drug is likely to defend the title of King of Medicine in 2024. However, on November 6, after Novo Nordisk released its third-quarter report, the competition for the King of Medicine caused a stir. In the first three quarters, the total sales of multiple versions of semaglutide reached US$20.3 billion, approaching K drug. Such a limited gap also indicates the fierceness of the competition for the King of Medicine. Before the results of the fourth quarter are announced, no one knows the final answer. Will K drug become the “shortest-lived King of Medicine” in history? On February 1, 2024, with the ...
- Source: drugdu
- 55
- November 8, 2024
GLP-1 counterfeit drugs rampant, Lilly will file another lawsuit

Eli Lilly has taken further legal action against the continuous emergence of counterfeit products of Tilpotide. Recently, Eli Lilly has filed a lawsuit against three suppliers of counterfeit tiltrotide products that have not been approved by the FDA. The company is seeking a court order to stop the sale of these counterfeit tiltrotide products and demand economic compensation from these suppliers. The rampant use of counterfeit drugs The soaring demand for GLP-1 has not only made Novo Nordisk and Eli Lilly one of the most valuable companies in Europe, but also led to long-term supply shortages around the world. In order to get a share of the pie, some illegal merchants have engaged in rampant counterfeiting and forgery of the products of the two companies. These unregulated counterfeit drugs pose significant risks to the health of patients and may even endanger their lives. In December last year, the FDA issued ...
- Source: drugdu
- 59
- October 26, 2024
GCGR agonist rejected twice

Original Time Biopharmaceutical Editor October 14, 2024 09:20 Shanghai The weight loss drug concept stock Zealand has suffered another setback, as its new drug Dasiglucagon, which was launched to treat congenital hyperinsulinemia (CHI) in children, has once again been rejected by the FDA. Last December, Dasiglucagon was rejected by the FDA for the first time due to the discovery of defects in a third-party contract manufacturing factory. Zealand pointed out that the main reason for Dasiglucagon’s second rejection was that the FDA failed to complete the re inspection of third-party production factories, resulting in the approval process being put on hold. The FDA did not raise any concerns about the effectiveness or safety of Dasiglucagon. Dasiglucagon is a glucagon receptor (GCGR) agonist that acts to release stored glycogen from the liver into the bloodstream. Hypoglycemia is one of the most common acute complications of diabetes, and patients who have the ...
- Source: drugdu
- 62
- October 15, 2024
Wealth myth” of GLP-1

Recently, the Lasker Award, an important award in the field of biomedicine known as the “vane” of the Nobel Prize, was announced. Among them, the “Clinical Medical Research Award” was awarded to Joel Habener (Massachusetts General Hospital), Lotte Bjerre Knudsen (Novo Nordisk) ) and Svetlana Mojsov (Rockefeller University). The reason for the award is that they discovered and developed GLP-1-based drugs, which revolutionized the treatment of obesity. GLP-1, glucagon-like peptide-1, is a peptide hormone encoded by the human glucagon gene and secreted by intestinal L cells. It can promote the synthesis and secretion of insulin and suppress appetite. Delaying the emptying of gastric contents, etc. Representative products include Novo Nordisk’s semaglutide and Eli Lilly’s tilpotide. It is worth mentioning that the research on GLP-1 has not only received attention from academic awards, but also brought “vast wealth” to companies in the industrial chain due to the huge market demand. The ...
- Source: drugdu
- 94
- September 25, 2024
$1.8 billion! Lilly builds factory and expands GLP-1 production

Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice. Lilly said that the company had completed the $800 million Kinsale factory expansion project to increase the production of its obesity and diabetes drugs Mounjaro and Zepbound. At the same time, the pharmaceutical company will also invest $1 billion to build a factory in Limerick to increase the production of biopharmaceutical raw materials, especially Kisunla, a drug approved by the FDA to treat Alzheimer’s disease two months ago. The production of active pharmaceutical ingredients is expected to begin in 2026. Lilly stated that Limerick’s expansion will add tools for artificial intelligence, automated robots, and machine learning to the website. ...
- Source: drugdu
- 77
- September 16, 2024
semaglutide is gaining ground

As we enter 2024, the global competition for “King of Medicine” is becoming increasingly fierce. In the first half of the year, Merck’s PD-1 monoclonal antibody pembrolizumab (trade name: Keytruda, “Keytruda”) successfully won the title of the world’s “king of medicine” with $14 billion. Novo Nordisk’s semaglutide (including 3 brands: Ozempic/Rybelsus/Wegovy) ranked second with sales of about $13 billion in the first half of this year, further narrowing the gap with Keytruda, and the year-on-year growth rate exceeded 40%, leaving suspense for the “king of medicine” competition in the second half of the year. On the other hand, in terms of sales growth, Eli Lilly’s tirpotide (including two brands: Mounjaro/Zepbound) grew 330% year-on-year in the first half of this year to $6.658 billion, making it the fastest-growing drug in history. Since its first indication was approved in 2022, it has grown into a super blockbuster with annual sales of over ...
- Source: drugdu
- 65
- September 5, 2024
The Low Point of Performance Due to Centralized Procurement Has Passed, and Tonghua Dongbao Ushered in a Stable Development Period

On the evening of August 30, Tonghua Dongbao (600867.SH) released its 2024 semi-annual report, during the report period, the company achieved operating income of about 740 million yuan, a year-on-year decrease of 45.84%; net profit attributable to shareholders of listed companies of about -230 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of about -0.13 billion yuan. Industry analysts believe that the reason why Tonghua Dongbao fell into a loss, stemming from the biggest cyclical factors – insulin special centralized procurement. Similar to the first centralized procurement, the results of this year’s renewal have not been reflected in the performance for the time being. The main reason for the company’s first-half performance fluctuations is a one-time dealer to make up the difference, which was also the case in the last centralized procurement, fell to a low point in the second quarter, the ...
- Source: drugdu
- 80
- September 5, 2024
AstraZeneca grows oncology portfolio with Pinetree’s EGFR degrader

AstraZeneca has signed a licensing agreement with Pinetree Therapeutics for a preclinical epidermal growth factor receptor (EGFR) degrader candidate, potentially worth more than $545m. AstraZeneca will pay $45m upfront for global developmental and commercialisation rights for the pan-EGFR degrader, and Pinetree will also be in line to receive up to $500m in milestone-based payments along with tiered royalties on sales. “[The] pan-EGFR degrader was developed from AbReptor, our proprietary multispecific antibody platform and has demonstrated promising preclinical anti-tumour activity in drug-resistant and tyrosine kinase inhibitor (TKI)-resistant tumours, as well as enhanced activity when used in combination with current EGFR inhibitors,” said Dr Hojuhn Song, founder and CEO of Pinetree. Targeted protein degraders, often called molecular glues, have been a growing area of interest in recent years. Most of these therapies are developed in oncology. According to GlobalData’s drug database, over 200 therapies in development have been classified as molecular glue ...
- Source: drugdu
- 91
- July 26, 2024
German CDMO outlays $980m on GLP-1 manufacturing expansion

German contract development and manufacturing organisation (CDMO) Corden Pharma announced a €900m ($980m) investment to expand its diabetes drug manufacturing capabilities, as shortages persist around the world. The company declared that the investment would be used over the next three years to expand its peptide manufacturing capabilities at sites in Colorado, US, and Europe. The facilities will have a particular focus on GLP-1 peptide manufacturing, as the demand increases. In a 16 July press release, the company spoke of multiple long-term contracts worth more than €3bn with potential benefits. Last year, the company signed a major deal with Eli Lilly to manufacture the active pharmaceutical ingredient for its leading obesity drug Mounjaro (tirzepatide), as per a Reuters report. In January 2023, the company also shared the signing of a $1bn multi-year agreement to manufacture a large volume peptide with an undisclosed company. The latest investment will be used to construct ...
- Source: drugdu
- 75
- July 19, 2024
Tau-Focused Asceneuron Adds $100M as Oral Alzheimer’s Drug Advances to Phase 2 Trial

Novo Holdings led Asceneuron’s $100 million Series C financing. The Merck Serono spinout’s lead program is an oral small molecule designed to prevent aggregation of tau protein in neurodegenerative disorders. By Frank Vinluan Alzheimer’s disease patients can now choose between new two intravenously infused therapies that work by breaking up plaques of amyloid protein in the brain. Asceneuron takes a different approach with oral therapies that address the buildup of tau, a protein that’s also associated with the neurodegenerative disorder. The biotech now has $100 million to advance its lead program to Phase 2 testing. The Series C financing announced Tuesday was led by Novo Holdings, the company that manages the assets of the Novo Nordisk Foundation, the controlling shareholder of metabolic drug giant Novo Nordisk. Using a drug to target and break up pathological proteins associated with Alzheimer’s has been validated by Eisai’s Leqembi, approved by the FDA last year, ...
- Source: drugdu
- 140
- July 18, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.